 meet management reaffirm convict
messag host meet ceo mike kaufmann interim cfo david
evan believ everyth bed rose compani believ
inflect fundament underappreci current
expect guidanc valuat level greatest risk buy rate remain
opioid settlement may greater expect point believ
investor ratchet expect front mani outcom
could serv posit clear event share pleas see takeaway
bodi note reiter buy rate rais pt
bottom line share cardin sinc mid august compar
believ recent strength due combin macro shift
valu across broader market also number company-specif factor includ
conserv guidanc way recent improv rhetor around
moder gener deflat increas view opioid settlement could
manag revers mean lowest multipl suppli chain
upgrad note detail continu believ cah guidanc
conserv believ opioid settlement sever impact
investor may expect detail thought also believ spin medic
segment inevit road unlock potenti valu even
recent strength share cardin remain cheapest stock suppli channel
estim ebitda
take-away opioid litig varieti potenti outcom without
clear timelin opioid litig continu primari sourc investor concern
regard drug distributor manag limit term abil discuss
matter offer help color situat broadli compani
continu defend believ behav inappropri relat
control substanc believ compani divers effort fairli
repres mainstream media align comment receiv
recent convers industri execut suggest distributor
transpar activ regulatori bodi suffici
provid guidelin industri view answer like somewher
believ distributor probabl share wrongdo
think broader media coverag may also overli one-sid relat litig
manag offer high-level thought rang outcom type
settlement compani would need feel fair/inclus potenti parti
would includ suffici regulatori guidelin path forward settlement
could includ cash payment also certain type in-kind servic mdl trial
set start one month time grow increasingli skeptic all-
encompass settlement reach near-term expect grow
chanc trial date may push later calendar year believ
involv parti interest settlement trial agreement
appear horizon judg like delay time trial
balanc sheet/cash impact addit size settlement investor
larg concern compani abil financ potenti settlement
respect balanc sheet capit deploy manag reiter focu
maintain level capital-expenditure maintain dividend current
share count continu delev debt paydown expect
compani proceed slowli repurchas given uncertainti
settlement negoti view roughli free cash flow like
posit digest outcom free cash flow gener maintain
capit expenditur dividend particularli anticip potenti
settlement span long time-frame like year mind one
page analyst certif import disclosur
potenti way assess opioid litig assum compani suspend futur
share repurchas pay fine exampl pay fine
year would repres annual payment current share
price share count would repres opportun cost
earn power repurchas would also note distributor may also
posit renegoti term supplier need help aid cash flow
time period overal appreci potenti fine much wors
front-load financi impact also believ risk well understood
investor larg embed expect mani
outcom could posit clear event share
take-away gener deflat seem trend favor manag
reiter view call sell-sid deflat compon gener
program improv manag assum deflat whole improv
y/i vs addit compani expect overal gener program
includ impact purchas save new introduct volum less
headwind y/i vs although still headwind although
import nuanc compani discuss gener price believ cah
commentari reinforc gener improv tone across industri respect
deflat suggest buy-sid gener deflat mid-ish singl digit rang
potenti move toward low singl digit move econom
cycl describ environ competit stabl describ
gener deflat low-singl digit overal encourag see
stabilization/improv price environ continu trend could
help profit rel investor expect
take-away brand inflat trend expect similar y/i
manag expect brand inflat similar limit impact
price behavior polit environ manag also account
variabl brand inflat within outlook believ deviat even
vs current expect would abl digest within current ep guidanc
rang encourag manag price commentari
abil absorb potenti volatil believ investor alreadi brace
modest brand inflat trend
take-away save tailwind
manag anticip increment cost save spread
across pharmaceut medic segment cost save seem
weight toward medic divis estim toward medic reason
manag note save fall bottom line
reinvest busi believ give manag team flexibl
adjust magnitud cadenc invest order meet overal expect
year alway risk disrupt restructur effort
cost save initi believ like tie long-overdu realiz
synergi effici across enterpris
take-away segment outlook continu feel conserv
key area focu investor magnitud impli oper margin
deterior compani outlook pharmaceut segment manag
highlight key factor signific repric
kr contract took effect juli would note contract
renew longer typic termscv year least year
could result increment price concess
annual step price embed contract may caus
larger initi price concess continu believ compani like embed
conservat outlook particularli given improv sell-sid gener deflat
environ upcom cost save seemingli less signific impact experienc
competitor larg recent renew
manag highlight three largest contract roughli pharmaceut
revenu recent renew expir least four year optum
part recent sign six-year contract expir sign four
year contract expir sign contract length least
four year expir later respect particular
page analyst certif import disclosur
manag highlight contract emb annual step price
suggest present increment headwind beyond
renew rearview note revenu contract
least four year believ remain like renew ratabl
year usual three year contract encourag level visibl
go forward potenti limit profit headwind horizon
stem renew
compani lap estim charg taken
would repres y/i growth tailwind moreov manag
expect cost save effort disproportion benefit medic segment estim
impact mind believ medic segment
outlook like emb conservat well appreci histor
challeng segment sign stabil encourag
expect feel achiev also believ worth note manag reiter
confid new leadership team abil stabil busi
take-away manag seem open mind toward portfolio
manag seem prudent unemot approach manag variou
assets/busi current portfolio manag emphas alway put
sharehold valu first afraid take action necessari note
compani recent exit china oper also sold major ownership
navihealth demonstr willing make necessari strateg decis
respect medic divis compani acknowledg histori disappoint
result continu believ busi perform well outlook impli
welcom stabil y/i publish past believ
spin-off medic segment like believ could gener sharehold
valu spin manag offer indic possibl
sens ceo less attach medic busi prior manag
team embark strategi encourag open-mind
approach portfolio compani seem intent continu invest medic
near-term continu believ manag pressur conduct
broad-bas strateg review medic divis result improv
take-away recent execut turnov seem driven uniqu
circumst recent experienc meaning execut turnov
departur compani cfo well ceo medic divis sinc
compani appoint interim cfo david evan new medic divis ceo
stephen mason manag emphas recent departur uniqu
circumst relat specif individu confid abil attract
talent view select perman cfo particularli import hire
compani bring potenti new leadership fresh perspect
compani near-term manag appear confid mr evan abil
execut role interim respect medic divis manag also
reiter confid stephen mason new leader admittedli somewhat
concern mr mason seem come sale orient background believ
investor anticip execut manufactur background
take-away specialti busi continu area strength specialti
area strength distributor cah busi continu grow
nice year manag emphas satisfact perform
part portfolio note abl take share
competitor cah specialti busi grown organ acquisit
estim approach consider smaller
specialti busi still healthi contributor overal perform
primari concern front continu around evolut medicar part
regul impact specialti price distribut suppli chain
valuat risk rais price target base
ev/ebitda line peer group averag higher
target multipl vs previous reflect increas confid manag abil
navig difficult environ target valuat repres discount
averag multipl howev believ discount warrant given uncertainti
medic busi linger opioid litig given price target
impli upsid current trade level reiter buy rate believ
page analyst certif import disclosur
biggest risk downsid pend opioid litig particularli given
uncertainti around potenti size time settlement fine addit note
risk less favor brand gener price trend
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
